Esperion Therapeutics to Present at Bank of America Merrill Lynch Healthcare Conference

Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company will present at the 2014 Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nev. Tim M. Mayleben, president and chief executive officer, will provide updates on the company on Tuesday, May 13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at investor.esperion.com/events. A webcast replay of the call will be available approximately one hour after completion of the call and will be archived on the Company's website for approximately 90 days following the event.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently-available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com.